Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus DEMECLOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus DEMECLOCYCLINE HYDROCHLORIDE.
ATRIDOX vs DEMECLOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic